Prediction of Risk of Disease Progression and Death in CML After Imatinib Treatment


Prediction of Risk of Disease Progression and Death in CML After Imatinib Treatment
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Srdan Verstovsek, MD, PhD (1/25/12)

Hanfstein B et al. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients — A follow-up analysis of the German CML study IV. Proc ASH 2011;Abstract 783.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.